656PSustained functional improvement with DYNE-251 in males with DMD mutations amenable to exon 51 skipping enrolled in the phase 1/2 DELIVER trial
M. Guglieri, Douglas S. Kerr(University of Otago), N. Deconinck, Satyajit Ray, K. Flanigan, A. Dugar(Sarepta Therapeutics (United States)), Martin Naylor, Dajiang Wang, Perry B. Shieh(Boston Children's Hospital), M. Lorentzos, Craig Campbell(Children's Hospital of Western Ontario), H. Phan(Rare Disease Therapeutics (United States)), L. De Waele
Cited by 0
Related Papers
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy
|JAMA Neurology|2020|387
Recessive truncating titin gene, <i>TTN</i> , mutations presenting as centronuclear myopathy
|Neurology|2013|217
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial
|Nucleic Acid Therapeutics|2021|128